Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.36 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | FURIN | P09958 | 4/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27094864 | 0.87 | C3AR1 (0.38) | C3AR1FURINEPHX2POLBPRSS1 | |
| SCHEMBL19432348 | 0.85 | KMT2A (0.41) | KMT2AITGB3ITGA2BFURINEPHX2 | |
| SCHEMBL22068145 | 0.84 | C3AR1 (0.36) | KMT2AITGB3ITGA2BC3AR1FURIN | |
| SCHEMBL20800175 | 0.79 | GNPAT (0.49) | C3AR1FURINPOLBNOD1 | |
| SCHEMBL17987754 | 0.79 | MAP1LC3B (0.37) | KMT2AALDH1A1FURINHRH1 | |
| SCHEMBL29284569 | 0.78 | NPC1 (0.41) | KMT2ANPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL29284586 | 0.78 | NPC1 (0.41) | KMT2ANPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL29284547 | 0.78 | NPC1 (0.41) | KMT2ANPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL21607789 | 0.77 | C3AR1 (0.43) | C3AR1FURINEPHX2POLBPRSS1 | |
| SCHEMBL26223141 | 0.77 | C3AR1 (0.43) | C3AR1FURINEPHX2POLBPRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293536-A1 | ANTI-ERBB2 ANTIBODY-DRUG CONJUGATE AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20220008553-A1 | ANTI-ERBB2 ANTIBODY-DRUG CONJUGATE AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2022-01-13 | — | — | US | disclosed |
| US-20210252006-A1 | ANTI-ERBB2 ANTIBODY-DRUG CONJUGATE AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-08-19 | — | — | US | disclosed |
| US-20190076438-A1 | ANTI-ERBB2 ANTIBODY-DRUG CONJUGATE AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190076438-A1 | ANTI-ERBB2 ANTIBODY-DRUG CONJUGATE AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | ERBB2, ERBB3, EGFR | KMT2A 1245/4885NPC1 1378/4885RAB9A 2821/4885 |
| US-20230293536-A1 | ANTI-ERBB2 ANTIBODY-DRUG CONJUGATE AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | ERBB2, ERBB3, EGFR | KMT2A 1248/4885NPC1 1352/4885RAB9A 2750/4885 |
| US-20210252006-A1 | ANTI-ERBB2 ANTIBODY-DRUG CONJUGATE AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | ERBB2, EGFR, ERBB3 | KMT2A 1249/4885NPC1 1704/4885RAB9A 1837/4885 |
| US-20220008553-A1 | ANTI-ERBB2 ANTIBODY-DRUG CONJUGATE AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | ERBB2, EGFR, ERBB3 | KMT2A 1017/4885NPC1 1637/4885RAB9A 2175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.